The Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Clinical Application of New Therapeutic Strategies

• Váldodahkkit: Carmelo Laface (Dahkki), Felicia Maria Maselli (Dahkki), Anna Natalizia Santoro (Dahkki), Maria Laura Iaia (Dahkki), Francesca Ambrogio (Dahkki), Marigia Laterza (Dahkki), Chiara Guarini (Dahkki), Pierluigi De Santis (Dahkki), Martina Perrone (Dahkki), Palma Fedele (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: MDPI AG, 2023-05-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Almost 17% of Western patients affected by non-small cell lung cancer (NSCLC) have an activating epidermal growth factor receptor (EGFR) gene mutation. Del19 and L858R are the most-common ones; they are positive predictive factors for EGFR tyrosine kinase inhibitors (TKIs). Currently, osimertinib, a...